In this Blood Advances Talk, I discuss the current therapeutic landscape of FLT3 inhibitors. We now have a new drug, midostaurin, which is a part of the standard of care for patients with FLT3-mutant acute myeloid leukemia. However, the field is clearly “on the move,” as there are more than half a dozen randomized trials of FLT3 inhibitors accruing right now, and off-label use of sorafenib also remains an option for some practitioners. These different inhibitors, all with strengths and weaknesses, are being studied in almost every aspect of the disease, from diagnosis to relapse to maintenance, in both fit and unfit patients. Therefore, although it is an exciting time for our field, there remain many uncertainties about how changes will unfold going forward. I hope to offer some clarification on these issues in this talk.

Download or subscribe to the Blood Advances Talk podcast at

The complete text of this Blood Advances Talk is available as a data supplement.

Contribution: M.L. wrote this article.

Conflict-of-interest disclosure: M.L. has received research funding from Novartis and Astellas, and has participated in advisory committees for Novartis, Astellas, Daiichi-Sankyo, and Arog.

Correspondence: Mark Levis, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans St, Room 2M44, Baltimore, MD 21287; e-mail:

Supplemental data